Latest Dana-Farber Cancer Institute Stories
Scientists reported on Wednesday that they have sequenced the entire genetic code of 38 multiple myeloma patients, and have uncovered the most likely genetic causes of the aggressive blood cancer.
Dana-Farber Cancer Institute scientists report they have shrunk or slowed the growth of notoriously resistant pancreatic tumors in mice, using a drug routinely prescribed for malaria and rheumatoid arthritis.
Using whole genome sequencing and multiple tumor samples, researchers uncover genes tied to prostate cancer growth.
Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively.
By tweaking a single gene, scientists have mimicked in sedentary mice the heart-strengthening effects of two weeks of endurance training.
In early results, all participants responded to treatment with limited side effects ANN ARBOR, Mich., Dec.
A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients.
In research to be presented at the American Society of Hematology (ASH) annual meeting, investigators at Dana-Farber Cancer Institute in Boston offer a new explanation of why chronic lymphocytic leukemia (CLL) tends to recur in the lymph nodes and bone marrow after being cleared from the bloodstream by chemotherapy.
NEWTON, Mass., Nov. 3, 2010 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has completed a $20M Series A financing.
A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein.
- One of a pair of round metal cymbals attached to the fingers and struck together for rhythm and percussion in belly dancing.